Literature DB >> 15981236

Cytogenetic evaluation of a large series of hepatoblastomas: numerical abnormalities with recurring aberrations involving 1q12-q21.

Gail E Tomlinson1, Edwin C Douglass, Brad H Pollock, Milton J Finegold, Nancy R Schneider.   

Abstract

Hepatoblastoma is a malignant embryonal liver tumor that occurs almost exclusively in infants and very young children. Previous cytogenetic studies of hepatoblastoma have investigated small series or individual cases. This report is on the cytogenetics of a large series of 111 hepatoblastoma specimens, with cytogenetic results consecutively karyotyped over a 12-year period. Abnormal karyotypes were observed in 55 cases (approximately 50% of the total). Numerical aberrations were observed in 41 cases (36% of the total), particularly trisomies of chromosomes 2, 8, and 20. Chromosome losses were less common than chromosome gains. Structural abnormalities were observed in 43 cases (39% of the total). Unbalanced translocations resulting in trisomy 1q and involving breakpoints at 1q12-21 were the most common structural abnormality, observed in 20 tumors (18% of total cases); the corresponding translocated chromosome was highly varied. The previously reported t(1;4) was observed in seven cases. Most tumors with translocations involving 1q12-21 also displayed numerical chromosome aberrations, the most common of which were chromosomal trisomies, whereas tumors with other structural rearrangements had fewer numerical abnormalities.

Entities:  

Mesh:

Year:  2005        PMID: 15981236     DOI: 10.1002/gcc.20227

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  13 in total

1.  Hepatoblastoma modeling in mice places Nrf2 within a cancer field established by mutant β-catenin.

Authors:  Sarah A Comerford; Elizabeth A Hinnant; Yidong Chen; Hima Bansal; Shawn Klapproth; Dinesh Rakheja; Milton J Finegold; Dolores Lopez-Terrada; Kathryn A O'Donnell; Gail E Tomlinson; Robert E Hammer
Journal:  JCI Insight       Date:  2016-10-06

Review 2.  Current and future management strategies for relapsed or progressive hepatoblastoma.

Authors:  Rajkumar Venkatramani; Wayne L Furman; Joerg Fuchs; Steven W Warmann; Marcio H Malogolowkin
Journal:  Paediatr Drugs       Date:  2012-08-01       Impact factor: 3.022

3.  MYBL2 accelerates epithelial-mesenchymal transition and hepatoblastoma metastasis via the Smad/SNAI1 pathway.

Authors:  Meng Wei; Ran Yang; Mujie Ye; Yong Zhan; Baihui Liu; Lingdu Meng; Lulu Xie; Min Du; Junfeng Wang; Runnan Gao; Deqian Chen; Rui Dong; Kuiran Dong
Journal:  Am J Cancer Res       Date:  2022-05-15       Impact factor: 5.942

Review 4.  Children's Oncology Group's 2013 blueprint for research: rare tumors.

Authors:  Carlos Rodriguez-Galindo; Mark Krailo; Lindsay Frazier; Murali Chintagumpala; James Amatruda; Howard Katzenstein; Marcio Malogolowkin; Logan Spector; Farzana Pashankar; Rebecka Meyers; Gail Tomlinson
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

5.  Gene expression profiling reveals signatures characterizing histologic subtypes of hepatoblastoma and global deregulation in cell growth and survival pathways.

Authors:  Adekunle M Adesina; Dolores Lopez-Terrada; Kwong K Wong; Preethi Gunaratne; Yummy Nguyen; Joseph Pulliam; Judith Margolin; Milton J Finegold
Journal:  Hum Pathol       Date:  2009-02-05       Impact factor: 3.466

Review 6.  Rare Tumors in Children: Progress Through Collaboration.

Authors:  Alberto S Pappo; Wayne L Furman; Kris A Schultz; Andrea Ferrari; Lee Helman; Mark D Krailo
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

7.  Insights Into the Somatic Mutation Burden of Hepatoblastomas From Brazilian Patients.

Authors:  Talita Ferreira Marques Aguiar; Maria Prates Rivas; Silvia Costa; Mariana Maschietto; Tatiane Rodrigues; Juliana Sobral de Barros; Anne Caroline Barbosa; Renan Valieris; Gustavo R Fernandes; Debora R Bertola; Monica Cypriano; Silvia Regina Caminada de Toledo; Angela Major; Israel Tojal; Maria Lúcia de Pinho Apezzato; Dirce Maria Carraro; Carla Rosenberg; Cecilia Maria Lima da Costa; Isabela W Cunha; Stephen Frederick Sarabia; Dolores-López Terrada; Ana Cristina Victorino Krepischi
Journal:  Front Oncol       Date:  2020-05-05       Impact factor: 6.244

8.  Mutation, methylation, and gene expression profiles in dup(1q)-positive pediatric B-cell precursor acute lymphoblastic leukemia.

Authors:  Rebeqa Gunnarsson; Sebastian Dilorenzo; Kristina B Lundin-Ström; Linda Olsson; Andrea Biloglav; Henrik Lilljebjörn; Marianne Rissler; Per Wahlberg; Anders Lundmark; Anders Castor; Mikael Behrendtz; Thoas Fioretos; Kajsa Paulsson; Anders Isaksson; Bertil Johansson
Journal:  Leukemia       Date:  2018-03-12       Impact factor: 11.528

9.  NRAS and KRAS polymorphisms are not associated with hepatoblastoma susceptibility in Chinese children.

Authors:  Tianyou Yang; Yang Wen; Jiahao Li; Tianbao Tan; Jiliang Yang; Jing Pan; Chao Hu; Yuxiao Yao; Jiao Zhang; Yijuan Xin; Suhong Li; Huimin Xia; Jing He; Yan Zou
Journal:  Exp Hematol Oncol       Date:  2019-05-09

Review 10.  The Curious Case of the HepG2 Cell Line: 40 Years of Expertise.

Authors:  Viktoriia A Arzumanian; Olga I Kiseleva; Ekaterina V Poverennaya
Journal:  Int J Mol Sci       Date:  2021-12-04       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.